Endometrial Cancer Clinical Trials (as in March 2017)

ENGOT-EN1-I/NSGO/FANDANGO

Leading group: NSGO

Clinical Trial Study: Randomized phase II trial of first-line combination chemotherapy with BIBFI 120 or placebo for patients with advanced or reccurrent cancer. (M. R. Mirza)

Number of patients accrued: 148

Planned number of patients: 150

Participating groups:

BGOG, GINECO, NOGGO

 

 

ENGOT-EN2/NSGO/DGCG/EORTC-55102

Leading group: NSGO

Clinical Trial Study: Adjuvant chemotherapy in node negative endometrial carcinoma. (M. R. Mirza)

Number of patients accrued: TBA

Planned number of patients: 240

Participating groups:

BGOG, CEEGOG, EORTC, GEICO, ISGO, MaNGO, MITO, NOGGO, (C-COG)

 

 

ENGOT-EN3/NSGO/PALEO

Leading group: NSGO

Clinical Trial Study: A randomized phase II trial of Palbociclib in combination with letrozole versus letrozole for patients with oestrogen receptor positive recurrent endometrial cancer

Number of patients accrued: 78

Planned number of patients: 80

Participating groups:

GEICO, MITO, NOGGO

 

 

ENGOT-EN4/NCRI/STATEC

Leading group: NCRI

Clinical Trial Study:

STATEC: A randomised trial of non-Selective versus selective adjuvant Therapy in high risk Apparent sTage 1 Endometrial Cancer

Number of patients accrued: will start in 2017

Planned number of patients: 2000

Participating groups:

DGOG, (ANZGOG, KGOG)

 

 

ENGOT-EN5/BGOG- EN5/SIENDO

Leading group: BGOG

Clinical Trial Study: A randomized phase III trial of maintenance with Selinexor/placebo after combination chemotherapy for patients with advanced or reccurent endometrical cancer

Number of patients accrued: TBA

Planned number of patients: 126

Participating groups:

NSGO, other groups under discussion